Dinutuximab Beta at the HUS and the Toulouse Oncopole
Recruiting
- Conditions
- Neuroblastoma
- Registration Number
- NCT06275334
- Lead Sponsor
- University Hospital, Strasbourg, France
- Brief Summary
In this study the investigators wish to describe the cohort of pediatric patients suffering from neuroblastoma and treated with Dinutuximab and to compare the costs and quality of life between the two French centers, the University Hospital of Strasbourg (HUS) and the Oncopole of Toulouse.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Subjects aged 2 years to 25 years
- Male or female gender
- Subjects suffering from neuroblastoma and treated at the HUS or at the Oncopole center in Toulouse during the period from January 1, 1998 to December 31, 2023.
- Subject (and/or holders of parental authority) not opposing, after information, the reuse of the child's data for the purposes of this research and agreeing to respond to the quality of life survey.
Exclusion Criteria
- Patient or parents of the minor having expressed their opposition to participating in the study.
- specific clinical forms of the disease,
- interfering treatments and associated diseases.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of two methods of treating a pediatric pathology in two French health establishments, the HUS and the Oncopole of Toulouse. The period concerned is from January 1, 1998 to December 31, 2023. This study is retrospective and consists of comparing two methods of treating neuroblastoma in two health establishments and covers the period from January 1, 1998 to December 31, 2023.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Service de Pharmacie - Stérilisation - CHU de Strasbourg - France
🇫🇷Strasbourg, France